February 19, 2008 -The Pfizer Foundation announced a groundbreaking $33 million multi-year program to address the emerging challenges in cancer and tobacco control. The first round of the Global Health Partnerships grants has already been awarded to 15 non-governmental organizations (NGOs) in 26 countries around the world – from Algeria, China and Japan to Italy, Brazil and Argentina. The program reflects both the Pfizer Foundation and Pfizer’s global commitment to working with a diverse group of local NGO experts towards improving the diagnosis and treatment of cancer and reducing the disease’s incidence and burden.
Cancer accounts for one in eight deaths globally– more than AIDS, tuberculosis and malaria combined. In the 20th century, the tobacco epidemic killed 100 million people worldwide... Pfizer's Press Release-
Blog Archive
-
▼
2008
(297)
-
▼
February
(25)
- AstraZeneca RECENTIN BR24 Non-Small Cell Lung Canc...
- Aerocrine, Chest M.I. market and sell NIOX MINO in...
- N30 Pharma, Successful Initiation of Human Studies...
- Glenmark, USD 15 million as milestone payments fro...
- BioMarck Pharmaceuticals, FDA Agreement on its P...
- ADVENTRX, Complete ANX-530 Pharmacokinetic Data at...
- Hana Biosciences, Top-Line Phase 1 Clinical Trial ...
- Bayer and Onyx , Update on Phase 3 Trial of Nexava...
- Oncothyreon's PX-478, effective in preclinical mod...
- Strativa Pharmaceuticals, Discontinuation of the D...
- VioQuest Pharmaceuticals, Clinical Trial Agreement...
- GSK's Volibris (ambrisentan), EMEA positive opinio...
- UCB and sanofi-aventis, FDA Approves XYZAL® (levoc...
- Pfizer and The Pfizer Foundation, to Support Cance...
- GlaxoSmithKline, EMEA positive opinion for the app...
- Schering-Plough, ASMANEX (R) TWISTHALER(R) (Mometa...
- MedImmune submitted Biologics License Application...
- Pfizer Japan, Manufacturing and Marketing Authoriz...
- CAS Medical Systems, Placement of 50th FORE-SIGHT ...
- Masimo, New National Standard for CO Screening by ...
- Sanofi Pasteur and Statens Serum Institut , develo...
- TOPIGEN's TPI ASM8 , European Phase 2 Clinical Stu...
- GlaxoSmithKline and TB Alliance, Tuberculosis Drug...
- Sepracor and Nycomed : exclusive development, mark...
- EPIX Pharmaceuticals, Collaboration with Cystic Fi...
-
▼
February
(25)